MCID: ATS001
MIFTS: 63

Autistic Disorder malady

Categories: Mental diseases, Genetic diseases

Aliases & Classifications for Autistic Disorder

Aliases & Descriptions for Autistic Disorder:

Name: Autistic Disorder 38 12 24 42 14 69
Autism 12 24 29 3 14
Autistic Disorder of Childhood Onset 12 29
Kanner's Syndrome 12
Childhood Autism 12
Infantile Autism 12
Autistic 52

Characteristics:

HPO:

32
autistic disorder:
Inheritance heterogeneous sporadic multifactorial inheritance
Onset and clinical course childhood onset


Classifications:



Summaries for Autistic Disorder

Disease Ontology : 12 An autism spectrum disorder that is characterized by symptoms across all three symptom domains (communication, social, restricted repetitive interests and behaviors), delayed language development, and symptom onset prior to age 3 years.

MalaCards based summary : Autistic Disorder, also known as autism, is related to autism spectrum disorder and mental retardation with language impairment and with or without autistic features, and has symptoms including seizures, intellectual disability and eeg abnormality. An important gene associated with Autistic Disorder is SNRPN (Small Nuclear Ribonucleoprotein Polypeptide N), and among its related pathways/superpathways are Transmission across Chemical Synapses and Serotonergic synapse. The drugs Valproic Acid and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord, brain and testes, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 71 Autism is a neurodevelopmental disorder characterized by impaired social interaction, verbal and... more...

Related Diseases for Autistic Disorder

Diseases related to Autistic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 69)
id Related Disease Score Top Affiliating Genes
1 autism spectrum disorder 31.1 FMR1 FOXP2 HTR7 MECP2 OXT SLC6A4
2 mental retardation with language impairment and with or without autistic features 12.1
3 mental retardation with language impairment and autistic features 11.8
4 intellectual disability-severe speech delay-mild dysmorphism syndrome 11.4
5 adenylosuccinase deficiency 11.2
6 phelan-mcdermid syndrome 11.2
7 pervasive developmental disorder not otherwise specified 11.0
8 asperger syndrome susceptibility, x-linked 2 10.7
9 asperger syndrome susceptibility, x-linked 1 10.7
10 atypical autism 10.6
11 dry eye syndrome 10.3 HTR2A HTR7 SLC6A4
12 neurogenic bladder 10.3 HTR2A HTR7 SLC6A4
13 euthyroid sick syndrome 10.3 HTR2A MECP2 SLC6A4
14 nephronophthisis 13 10.3 HTR2A SLC6A4
15 alzheimer disease 17 10.3 HTR2A HTR7 SLC6A4
16 keratosis 10.2 HTR2A HTR7 OXT SLC6A4
17 hepatitis b reinfection following liver transplantation 10.2 HTR2A OXT SLC6A4
18 chronic conjunctivitis 10.2 GABRB3 HTR2A OXT RELN SLC6A4
19 preeclampsia/eclampsia 5 10.2 GABRB3 HTR2A HTR7 SLC6A4
20 pervasive developmental disorder 10.1
21 spastic paraplegia 6, autosomal dominant 10.1 GABRA5 GABRB3 MECP2 SNRPN
22 roifman-chitayat syndrome 10.1 GABRA5 GABRB3 OXT SNRPN
23 hepatitis d 10.1 HTR2A OXT SLC6A4
24 attention deficit-hyperactivity disorder 10.0
25 brugada syndrome 10.0 GABRB3 NLGN3 NLGN4X SLC6A4
26 ellis-van creveld syndrome 10.0 FMR1 HTR2A MECP2 SLC6A4
27 immunodeficiency, isolated 10.0 FMR1 MECP2 SLC6A4
28 personality disorder 9.9 FMR1 HTR2A HTR7 MECP2 OXT RELN
29 intellectual disability 9.9
30 schizophrenia 9.9
31 mutism 9.9
32 bipolar disorder 9.8
33 cerebritis 9.7
34 cytomegalovirus infection 9.7
35 rubella 9.7
36 obsessive-compulsive disorder 9.7
37 epilepsy 9.7
38 childhood-onset schizophrenia 9.7
39 rett syndrome 9.6
40 landau-kleffner syndrome 9.6
41 hypothalamic hamartomas 9.6
42 dermatitis 9.6
43 gilbert syndrome 9.6
44 atopic dermatitis 9.6
45 obesity 9.6
46 aphasia 9.6
47 turner syndrome 9.6
48 visual agnosia 9.6
49 agnosia 9.6
50 specific language impairment 9.6

Graphical network of the top 20 diseases related to Autistic Disorder:



Diseases related to Autistic Disorder

Symptoms & Phenotypes for Autistic Disorder

Human phenotypes related to Autistic Disorder:

32 (show all 12)
id Description HPO Frequency HPO Source Accession
1 seizures 32 HP:0001250
2 intellectual disability 32 HP:0001249
3 eeg abnormality 32 HP:0002353
4 delayed speech and language development 32 HP:0000750
5 stereotypy 32 HP:0000733
6 autism 32 HP:0000717
7 impaired use of nonverbal behaviors 32 HP:0000758
8 restrictive behavior 32 HP:0000723
9 lack of spontaneous play 32 HP:0000721
10 impaired ability to form peer relationships 32 HP:0000728
11 inflexible adherence to routines or rituals 32 HP:0000732
12 increased serum serotonin 32 HP:0003144

MGI Mouse Phenotypes related to Autistic Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.24 SLC6A4 SNRPN TSC2 CADPS2 EN2 FMR1
2 growth/size/body region MP:0005378 10.1 FMR1 GABRB3 MECP2 NLGN3 OXT PTEN
3 mortality/aging MP:0010768 9.97 NLGN3 OXT PTEN RELN SLC6A4 SNRPN
4 integument MP:0010771 9.86 FMR1 HTR7 MECP2 OXT PTEN RELN
5 nervous system MP:0003631 9.77 CADPS2 EN2 FMR1 GABRA5 GABRB3 HTR7
6 reproductive system MP:0005389 9.32 EN2 FMR1 GABRB3 MECP2 NLGN3 OXT

Drugs & Therapeutics for Autistic Disorder

Drugs for Autistic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 389)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2 99-66-1 3121
2
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
3 Piracetam Approved Phase 4 7491-74-9
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
5
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 19982-08-2 4054
6
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-56-6 439302 53477758
7
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
8
Minocycline Approved, Investigational Phase 4,Phase 2,Phase 1 10118-90-8 5281021
9
Milnacipran Approved Phase 4 92623-85-3 65833
10
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 113-45-1 4158
11
Olanzapine Approved, Investigational Phase 4,Phase 2,Phase 3 132539-06-1 4585
12
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
13
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
14
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
15
Donepezil Approved Phase 4,Phase 1,Phase 2 120014-06-4 3152
16
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
17
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
18
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 73-31-4 896
19
Choline Approved, Nutraceutical Phase 4 62-49-7 305
20 Anticonvulsants Phase 4,Phase 3,Phase 2
21 Antimanic Agents Phase 4,Phase 3,Phase 2
22 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
23 GABA Agents Phase 4,Phase 3,Phase 2
24 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
26 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Antibodies Phase 4,Phase 2
28 gamma-Globulins Phase 4,Phase 2
29 Immunoglobulins Phase 4,Phase 2
30 Immunoglobulins, Intravenous Phase 4,Phase 2
31 Rho(D) Immune Globulin Phase 4,Phase 2
32 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Early Phase 1
34 Etiracetam Phase 4
35 Neuroprotective Agents Phase 4,Phase 2,Phase 3
36 Nootropic Agents Phase 4,Phase 3,Phase 1,Phase 2
37 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
38 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
40 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
41 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
42 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
45 Excitatory Amino Acids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
46 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Respiratory System Agents Phase 4,Phase 2,Phase 3
50 Oxytocics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 790)
id Name Status NCT ID Phase
1 Divalproex Sodium ER in Adult Autism Unknown status NCT00211796 Phase 4
2 An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum Unknown status NCT02199925 Phase 4
3 Study to Evaluate the Efficacy and Safety of Aripiprazole Unknown status NCT02069977 Phase 4
4 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) Unknown status NCT00393614 Phase 4
5 Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART) Completed NCT01333072 Phase 4
6 Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder Completed NCT01227668 Phase 4
7 A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder Completed NCT00576732 Phase 4
8 Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism Completed NCT02235467 Phase 4
9 Minocycline to Treat Childhood Regressive Autism Completed NCT00409747 Phase 4
10 FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders Completed NCT01028820 Phase 4
11 Atomoxetine, Placebo and Parent Management Training in Autism Completed NCT00844753 Phase 4
12 A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders Completed NCT01333865 Phase 4
13 Omega-3 Fatty Acids in Autism Spectrum Disorders Completed NCT01695200 Phase 4
14 Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder Completed NCT00380692 Phase 4
15 Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism Completed NCT01337700 Phase 4
16 Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study Completed NCT02255565 Phase 4
17 A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD Completed NCT00485849 Phase 4
18 A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children Completed NCT01050582 Phase 4
19 Methylphenidate Study in Young Children With Developmental Disorders Completed NCT00517504 Phase 4
20 Metabolic Effects of Antipsychotics in Children Completed NCT00205699 Phase 4
21 Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder Completed NCT01238575 Phase 4
22 An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications. Completed NCT00391261 Phase 4
23 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders Recruiting NCT01098383 Phase 4
24 Gut to Brain Interaction in Autism. Role of Probiotics on Clinical, Biochemical and Neurophysiological Parameters Recruiting NCT02708901 Phase 4
25 Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD Recruiting NCT02096952 Phase 4
26 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Active, not recruiting NCT01339858 Phase 4
27 Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders Enrolling by invitation NCT02940574 Phase 4
28 Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders Terminated NCT01033565 Phase 4
29 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain Terminated NCT01844700 Phase 4
30 Oxytocin in Adolescents With Autism Spectrum Disorders Unknown status NCT02007447 Phase 2, Phase 3
31 Valproate Response in Aggressive Autistic Adolescents Unknown status NCT00065884 Phase 3
32 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3
33 Self-Injury: Diagnosis and Treatment Unknown status NCT00065936 Phase 3
34 Group Psychoeducational Program for Mothers of Children With High Functional Pervasive Developmental Disorders Unknown status NCT01243905 Phase 2, Phase 3
35 Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder Completed NCT00873509 Phase 2, Phase 3
36 A Trial of CM-AT in Children With Autism- Open Label Extension Study Completed NCT00912691 Phase 3
37 Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism Completed NCT00498173 Phase 3
38 A Trial of CM-AT in Children With Autism Completed NCT00881452 Phase 3
39 Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) Completed NCT00332241 Phase 3
40 A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder Completed NCT01617460 Phase 3
41 A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder Completed NCT01617447 Phase 3
42 Study of Fluoxetine in Autism Completed NCT00515320 Phase 3
43 Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) Completed NCT00337571 Phase 3
44 Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism Completed NCT01039792 Phase 2, Phase 3
45 A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder Completed NCT01624675 Phase 3
46 Treatment of Autism in Children and Adolescents Completed NCT00005014 Phase 3
47 Lurasidone Pediatric Autism Study Completed NCT01911442 Phase 3
48 Galantamine Versus Placebo in Childhood Autism Completed NCT00252603 Phase 3
49 Open-Label Extension Study of Kuvan for Autism Completed NCT00943579 Phase 2, Phase 3
50 Study of Paliperidone ER in Adolescents and Young Adults With Autism Completed NCT00549562 Phase 3

Search NIH Clinical Center for Autistic Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Autistic Disorder cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Autistic Disorder:
NU211-01/NC215-01, human umbilical cord mesenchymal stem cells for autism
Embryonic/Adult Cultured Cells Related to Autistic Disorder:
Umbilical cord-derived mesenchymal stem cells
Umbilical cord blood-derived mononuclear cells

Cochrane evidence based reviews: autistic disorder

Genetic Tests for Autistic Disorder

Genetic tests related to Autistic Disorder:

id Genetic test Affiliating Genes
1 Autistic Disorder of Childhood Onset 29
2 Autism 29
3 Autistic Disorder 24 SNRPN

Anatomical Context for Autistic Disorder

MalaCards organs/tissues related to Autistic Disorder:

39
Brain, Testes, Monocytes, Cortex, Amygdala
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Autistic Disorder:
id Tissue Anatomical CompartmentCell Relevance
1 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Autistic Disorder

Articles related to Autistic Disorder:

(show top 50) (show all 421)
id Title Authors Year
1
Serum and cerebrospinal fluid immune mediators in children with autistic disorder: a longitudinal study. ( 28070266 )
2017
2
Evidence of a reduction over time in the behavioral severity of autistic disorder diagnoses. ( 28102641 )
2017
3
Longitudinal association between early atopic dermatitis and subsequent attention-deficit or autistic disorder: A population-based case-control study. ( 27684861 )
2016
4
Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial. ( 27128958 )
2016
5
A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. ( 27316706 )
2016
6
Effects of augmentation agents in autistic disorder patients treated with risperidone: a systematic review and a meta-analysis. ( 27409138 )
2016
7
Comparing Efficacy and Side Effects of Memantine vs. Risperidone in the Treatment of Autistic Disorder. ( 27299475 )
2016
8
Lurasidone for the Treatment of Irritability Associated with Autistic Disorder. ( 26659550 )
2016
9
Effectiveness of switching from oral ziprasidone to risperidone in a patient with comorbid autistic disorder, profound intellectual disability, Gilbert syndrome, and exacerbation of psychosis. ( 26938829 )
2016
10
Pilot Study and Review: Physiological Differences in BDNF, a Potential Biomarker in Males and Females with Autistic Disorder. ( 26866045 )
2015
11
Brief Report: Parent-Reported Problems Related to Communication, Behavior and Interests in Children with Autistic Disorder and Their Impact on Quality of Life. ( 26438642 )
2015
12
Risk of cancer in children, adolescents, and young adults with autistic disorder. ( 25453246 )
2015
13
Female patient with autistic disorder, intellectual disability, and co-morbid anxiety disorder: Expanding the phenotype associated with the recurrent 3q13.2-q13.31 microdeletion. ( 26332054 )
2015
14
Efficacy and Safety of Aripiprazole for Treatment of Irritability in Children with Autistic Disorder: An Open-Label Study. ( 26538787 )
2015
15
Transcranial direct current stimulation for hyperactivity and noncompliance in autistic disorder. ( 25800799 )
2015
16
Kleine-Levin Syndrome in an 8-Year-Old Girl with Autistic Disorder: Does Autism Account a Primary or Secondary Cause? ( 26664444 )
2015
17
A 6q14.1-q15 microdeletion in a male patient with severe autistic disorder, lack of oral language, and dysmorphic features with concomitant presence of a maternally inherited Xp22.31 copy number gain. ( 26185640 )
2015
18
Low rates of depressed mood and depression diagnoses in a clinic review of children and adolescents with autistic disorder. ( 25198799 )
2014
19
Autism Detection in Early Childhood (ADEC): reliability and validity data for a Level 2 screening tool for autistic disorder. ( 24490680 )
2014
20
Risperidone-associated urinary incontinence in patients with autistic disorder with mental retardation. ( 25118082 )
2014
21
Effects of risperidone on core symptoms of autistic disorder based on childhood autism rating scale: an open label study. ( 24701014 )
2014
22
Sedation using 5% lidocaine patches, midazolam and propofol in a combative, obese adolescent with severe autistic disorder undergoing brain magnetic resonance imaging: a case report. ( 25558344 )
2014
23
The melatonin receptor agonist ramelteon effectively treats insomnia and behavioral symptoms in autistic disorder. ( 24955274 )
2014
24
Predictors of quality of life for fathers and mothers of children with Autistic Disorder. ( 24704547 )
2014
25
Validation of the World Health Organization's Quality of Life Questionnaire with parents of children with autistic disorder. ( 24696377 )
2014
26
A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. ( 24502859 )
2014
27
Autistic disorder in Nigeria: Profile and challenges to management. ( 25240124 )
2014
28
Smiling response, stranger anxiety, and autistic disorder. ( 23872942 )
2014
29
A randomised group comparison controlled trial of 'preschoolers with autism': A parent education and skills training intervention for young children with autistic disorder. ( 22987897 )
2014
30
Association of 5-HT2A receptor gene polymorphisms with gastrointestinal disorders in Egyptian children with autistic disorder. ( 25462508 )
2014
31
HPA and SAM axis responses as correlates of self- vs parental ratings of anxiety in boys with an Autistic Disorder. ( 24412722 )
2014
32
Psychosocial correlates of parenting a child with autistic disorder. ( 24731972 )
2014
33
Risk of autistic disorder after exposure to general anaesthesia and surgery: A nationwide, retrospective matched cohort study. ( 25101714 )
2014
34
Ramelteon monotherapy for insomnia and impulsive behavior in high-functioning autistic disorder. ( 24717259 )
2014
35
Interpregnancy interval and risk of autistic disorder. ( 24045716 )
2013
36
Maternal prenatal folic acid supplementation is associated with a reduction in development of autistic disorder. ( 23796343 )
2013
37
Parental perspectives on use, benefits, and physician knowledge of complementary and alternative medicine in children with autistic disorder and attention-deficit/hyperactivity disorder. ( 23621389 )
2013
38
Quality of life among parents of children with autistic disorder: A sample from the Arab world. ( 24316492 )
2013
39
Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. ( 23585028 )
2013
40
Transcranial Direct Current Stimulation for Autistic Disorder. ( 24342925 )
2013
41
Memantine-induced speech problems in two patients with autistic disorder. ( 23819879 )
2013
42
Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. ( 24138011 )
2013
43
In vitro fertilization and risk of autistic disorder and mental retardation. ( 23821086 )
2013
44
Deletion 1q43 encompassing only CHRM3 in a patient with autistic disorder. ( 23253743 )
2013
45
Magnetic resonance spectroscopy study of the glutamatergic system in adolescent males with high-functioning autistic disorder: a pilot study at 4T. ( 22986449 )
2013
46
An investigation of the security of caregiver attachment during middle childhood in children with high-functioning autistic disorder. ( 24072664 )
2013
47
Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder. ( 24052275 )
2013
48
Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. ( 23212807 )
2013
49
Epidemiology of autistic disorder in Bahrain: prevalence and obstetric and familial characteristics. ( 24313037 )
2013
50
Psychometric properties of the Parenting Stress Index with parents of children with autistic disorder. ( 23701497 )
2013

Variations for Autistic Disorder

ClinVar genetic disease variations for Autistic Disorder:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 CDKL5 NM_003159.2(CDKL5): c.183delT (p.Met63Cysfs) deletion Pathogenic rs62643608 GRCh37 Chromosome X, 18593511: 18593511
2 SCN2A NM_001040142.1(SCN2A): c.2229_2230delAC (p.Lys743Asnfs) deletion Pathogenic rs1057518658 GRCh38 Chromosome 2, 165331409: 165331410
3 GSPT2 NM_018094.4(GSPT2): c.1021G> A (p.Val341Ile) single nucleotide variant Pathogenic rs1057519440 GRCh37 Chromosome X, 51487743: 51487743

Copy number variations for Autistic Disorder from CNVD:

7 (show top 50) (show all 2458)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13764 1 1 28000000 Loss Autism
2 13902 1 10075582 11158005 Loss Autism
3 14098 1 103956056 104113271 Copy number Autism
4 14424 1 108105015 108110680 Gain VAV3 Autism
5 14687 1 109988334 109993086 Deletion or duplication Autism
6 14934 1 111291266 111291409 Loss C1orf103 Autism
7 15234 1 113734887 113735415 Loss MAGI3 Autism
8 15682 1 1180538 1207334 Copy number SDF4 Autism
9 15693 1 118296377 118296518 Gain WDR3 Autism
10 15989 1 1207568 1210341 Copy number B3GALT6 Autism
11 16771 1 1370430 1429557 Loss ATAD3B Autism
12 17284 1 142400000 148000000 Deletion Autism
13 17305 1 142400000 148000000 Duplication Autism
14 17328 1 142400000 148000000 Microdeletions and microduplications Autism
15 17370 1 142600000 147000000 Copy number Autism
16 17384 1 142600000 147000000 Deletion or duplication Autism
17 17385 1 142600000 147000000 Deletion or duplication Autism
18 18034 1 143650000 145000000 Loss Autism
19 18128 1 144124744 144396898 Loss Autism
20 18204 1 144337336 144456849 Gain Autism
21 18273 1 144838594 146308287 Gain BCL9 Autism
22 18300 1 144943150 145824905 Duplication ACP6 Autism
23 18301 1 144943150 145824905 Duplication BCL9 Autism
24 18302 1 144943150 145824905 Duplication CHD1L Autism
25 18303 1 144943150 145824905 Duplication FMO5 Autism
26 18304 1 144943150 145824905 Duplication GJA5 Autism
27 18305 1 144943150 145824905 Duplication PRKAB2 Autism
28 18318 1 144970329 145863421 Duplication Autism
29 18333 1 145013719 146293282 Loss Autism
30 18374 1 145119362 145761156 Gain Autism
31 18390 1 145303997 145357746 Deletion Autism
32 18391 1 145303997 145357746 Homozyg deletion Autism
33 19042 1 148307246 148307430 Gain VPS45 Autism
34 19443 1 150322696 150327314 Copy number S100A5 Autism
35 19590 1 150822223 150852849 Loss LCE3B Autism
36 19591 1 150822223 150852849 Loss LCE3C Autism
37 19764 1 151240762 151240937 Loss SPRR3 Autism
38 19944 1 152055312 152055457 Loss GATAD2B Autism
39 21488 1 1590917 1590971 Gain CDC2L1 Autism
40 22564 1 167493526 167507362 Loss NME7 Autism
41 23029 1 170820885 170824528 Gain C1orf9 Autism
42 23630 1 172142024 172310899 Gain RC3H1 Autism
43 23754 1 173697478 174026214 Gain TNR Autism
44 24014 1 174300000 178600000 Duplication PAPPA2 Autism
45 24015 1 174300000 178600000 Duplication RFWD2 Autism
46 24028 1 174500555 174543675 Duplication PAPPA2 Autism
47 24029 1 174500555 174543675 Duplication RFWD2 Autism
48 24297 1 178294383 178599040 Loss Autism
49 24421 1 180110206 180266346 Loss Autism
50 24441 1 180626647 180627201 Loss GLUL Autism

Expression for Autistic Disorder

Search GEO for disease gene expression data for Autistic Disorder.

Pathways for Autistic Disorder

GO Terms for Autistic Disorder

Cellular components related to Autistic Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.98 GABRA5 GABRB3 HTR2A HTR7 NLGN3 NLGN4X
2 dendrite GO:0030425 9.77 FMR1 GABRA5 HTR2A NLGN4X RELN
3 cell junction GO:0030054 9.7 CADPS2 FMR1 GABRA5 GABRB3 GABRG3 NLGN3
4 presynapse GO:0098793 9.58 CADPS2 FMR1 SLC6A4
5 chloride channel complex GO:0034707 9.5 GABRA5 GABRB3 GABRG3
6 synapse GO:0045202 9.5 CADPS2 FMR1 GABRA5 GABRB3 GABRG3 NLGN3
7 GABA-A receptor complex GO:1902711 9.46 GABRA5 GABRB3
8 postsynapse GO:0098794 9.43 FMR1 MECP2 NLGN3
9 postsynaptic membrane GO:0045211 9.17 CADPS2 FMR1 GABRA5 GABRB3 GABRG3 NLGN4X

Biological processes related to Autistic Disorder according to GeneCards Suite gene sharing:

(show all 38)
id Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.93 GABRA5 HTR2A HTR7 MECP2
2 response to estradiol GO:0032355 9.85 OXT PTEN SLC6A4
3 chloride transmembrane transport GO:1902476 9.83 GABRA5 GABRB3 GABRG3
4 chloride transport GO:0006821 9.83 GABRA5 GABRB3 GABRG3
5 brain development GO:0007420 9.83 GABRA5 MECP2 RELN SCT SLC6A4
6 response to nutrient GO:0007584 9.82 ADSL PTEN SLC6A4
7 negative regulation of neuron apoptotic process GO:0043524 9.8 EN2 GABRA5 GABRB3 MECP2
8 synapse assembly GO:0007416 9.77 MECP2 NLGN3 PTEN
9 positive regulation of synapse assembly GO:0051965 9.77 MECP2 NLGN3 OXT
10 neuron development GO:0048666 9.76 EN2 GABRA5 GABRB3
11 cerebellum development GO:0021549 9.71 FOXP2 MECP2 NLGN4X
12 vasoconstriction GO:0042310 9.68 HTR7 SLC6A4
13 regulation of N-methyl-D-aspartate selective glutamate receptor activity GO:2000310 9.67 NLGN3 RELN
14 neuron cell-cell adhesion GO:0007158 9.67 NLGN3 NLGN4X
15 learning GO:0007612 9.67 MECP2 NLGN3 NLGN4X RELN
16 vocalization behavior GO:0071625 9.66 NLGN3 NLGN4X
17 maternal behavior GO:0042711 9.66 OXT PTEN
18 regulation of respiratory gaseous exchange by neurological system process GO:0002087 9.65 MECP2 NLGN3
19 adult behavior GO:0030534 9.65 NLGN3 NLGN4X PTEN
20 sleep GO:0030431 9.64 HTR2A OXT
21 negative regulation of phosphatidylinositol 3-kinase signaling GO:0014067 9.63 PTEN TSC2
22 gamma-aminobutyric acid signaling pathway GO:0007214 9.63 GABRA5 GABRB3 GABRG3
23 multicellular organismal response to stress GO:0033555 9.62 MECP2 PTEN
24 negative regulation of organ growth GO:0046621 9.62 PTEN SLC6A4
25 regulation of behavior GO:0050795 9.61 HTR2A RELN
26 inner ear receptor cell development GO:0060119 9.61 GABRA5 GABRB3
27 inhibitory postsynaptic potential GO:0060080 9.58 GABRB3 NLGN3
28 positive regulation of excitatory postsynaptic potential GO:2000463 9.58 NLGN3 PTEN RELN
29 negative regulation of dendritic spine morphogenesis GO:0061002 9.57 NLGN3 PTEN
30 sperm ejaculation GO:0042713 9.56 OXT SLC6A4
31 male mating behavior GO:0060179 9.55 OXT PTEN
32 rhythmic synaptic transmission GO:0060024 9.52 NLGN3 PTEN
33 positive regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity GO:2000969 9.51 NLGN3 RELN
34 negative regulation of excitatory postsynaptic potential GO:0090394 9.5 NLGN3 NLGN4X PTEN
35 long-term synaptic potentiation GO:0060291 9.46 MECP2 NLGN3 PTEN RELN
36 presynaptic membrane assembly GO:0097105 9.43 NLGN3 NLGN4X PTEN
37 memory GO:0007613 9.35 HTR2A MECP2 OXT PTEN SLC6A4
38 social behavior GO:0035176 9.1 MECP2 NLGN3 NLGN4X OXT PTEN SLC6A4

Molecular functions related to Autistic Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 chloride channel activity GO:0005254 9.43 GABRA5 GABRB3 GABRG3
2 neurexin family protein binding GO:0042043 9.37 NLGN3 NLGN4X
3 serotonin binding GO:0051378 9.32 HTR2A HTR7
4 siRNA binding GO:0035197 9.16 FMR1 MECP2
5 extracellular ligand-gated ion channel activity GO:0005230 9.13 GABRA5 GABRB3 GABRG3
6 GABA-A receptor activity GO:0004890 8.8 GABRA5 GABRB3 GABRG3

Sources for Autistic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....